USPTO Allows Antibody Genus Claims in Patent Enabled by Integral Molecular's Paratope-PLUS CDR-Scanning

PR NewswireApr 21 08:03 ET

Integral to Book Major Profit Boost From Additional Fund III Carried Interest

TipRanksApr 6 04:52 ET

Integral Forecasts Major Earnings Boost From Additional Fund III Carried Interest

TipRanksMar 24 05:22 ET

Integral Molecular Appoints Cheryl Paes as Vice President of Commercial Strategy

PR NewswireMar 23 09:55 ET

Audit Consideration 25/12 = Integral: Based on unobservable inputs, impacting net profit or loss.

Submitter: Integral Co., Ltd. Submission Date and Time: March 19, 2026, 15:45 Submitted Document: Annual Securities Report Fiscal Year: 20th Term (From January 1, 2025, to December 31, 2025) <Key Audit Matters for Consolidated Financial Statements Count: 1> ▼ Fair Value Measurement of Financial Assets Measured at Fair Value Through Profit or Loss Based on Unobservable Inputs (Non-listed Equity Investments) <First Two Sentences> [Notes to Consolidated Financial Statements] 2

Jiji PressMar 19 02:48 ET

Integral: Confirmation Document

EDINETMar 19 02:47 ET · Announcements